Mayne Pharma Group Ltd
ASX:MYX
Operating Margin
Mayne Pharma Group Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| AU |
|
Mayne Pharma Group Ltd
ASX:MYX
|
408.7m AUD |
-28%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.9B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.3B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.2B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
185.9B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.7B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
198.9B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
136.3B USD |
27%
|
Mayne Pharma Group Ltd
Glance View
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Mayne Pharma Group Ltd's most recent financial statements, the company has Operating Margin of -28.4%.
You don't have any saved screeners yet